Amneal Pharmaceuticals Inc. Class A (AMRX)
Symbol Info
Listed Symbol AMRX
Name Amneal Pharmaceuticals Inc. Class A
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $1,662,991,000
Latest Fiscal EPS $-0.16
Price Info
21 Day Moving Average $3.1167
21 Day EMA $3.021800
50 Day Moving Average $2.9388
50 Day EMA $3.417110
200 Day EMA $8.161580
200 Day Moving Average 8.744950
52 Week High $21.22
52 Week Low $2.27
52 Week Change $-85.415500
Alpha -0.036689
Beta 1.4701
Standard Deviation 0.147525
R2 0.117224
Periods 60
Share Information
10 Day Average Volume 1,485,792
20 Day Average Volume 1,631,044
30 Day Average Volume 1,850,708
50 Day Average Volume 1,957,190
Outstanding Shares 299,091,265
Float Shares 298,054,700
Percent Float 99.65%
Short Interest 7,368,572
Short Percent Float 2.50%
Short Interest Ratio 3.67
Short Date 2019-09-13
Holders
Institutions 369
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 8,044,906
Institute Holdings Percent 42.000000
Institute Sold Previous 3 Months 14,156,419
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 5
Insider Holdings Percent 0.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,036,565
Price Change
7 Day Price Change $-0.4500001
7 Day Percent Change -14.20%
21 Day Price Change $-0.6199999
21 Day Percent Change -18.56%
30 Day Price Change $-0.74
30 Day Percent Change -21.39%
Month To Date Price Change $-0.18
Month To Date Percent -6.21%
90 Day Price Change $-1.33
90 Day Percent Change -32.84%
Quarter To Date $-0.18
Quarter To Date Percent -6.21%
180 Day Price Change $-10.7
180 Day Percent Change -79.73%
200 Day Price Change $-11.099999
200 Day Percent Change -80.32%
Year To Date $-10.809999
Year To Date Percent -79.90%
Profile
Description Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.
Details
Issue Type CS
Market Cap $813,528,241
Sec Type
Auditor Ernst & Young LLP
Total Shares Outstanding 299,091,265
CEO Chintu Patel / Chirag Patel
Employees 6,000
Last Audit UQ
Classification
CIK 0001723128
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 8807
Website https://www.amneal.com
Facisimile +1 908 947-3146
Telephone +1 908 947-3120
Email Invest@amneal.com
Key Ratios
Profitability
EBIT Margin 0.20
EBITDA Margin 12.6
Pre-Tax Profit Margin -
Profit Margin Cont -14.51
Gross Margin 31.90
Profit Margin TOT -14.51
Income Statements
Revenue $1,348,290,000
Revenue Per Share $10.5211
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $3,630,752,092
Price To Sales 0.258527
Price To Free Cash 7.800000
PE High Last 5 Years -
Price To Book 1.8
Price To Cash Flow 1.5
PE Low Last 5 Years -
Price To Tangible Book -0.6
Financial Strength
Total Debt To Equity 6.1
Int Coverage -
Current Ratio 2.2
Leverage Ratio 9.0
Quick Ratio 1.3
Long Term Debt To Capital 0.86
Assets
Receivables Turnover 1.1
Invoice Turnover 2.70
Assets Turnover 0.20
Management Effectiveness
Return Assets -1.51
Return On Equity -13.96
Return On Capital -2.04
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NYSE
AMRX
Amneal Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191018 05:58:29